Press Releases May 13, 2026 08:00 AM

Abacus Global Management to Participate in the 26th Annual B. Riley Investor Conference

Abacus Global Management announces participation in upcoming B. Riley Investor Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ABX

Abacus Global Management, a financial services company listed on the NYSE under ticker ABX, will participate in the 26th Annual B. Riley Investor Conference held May 20-21, 2026. Company executives will engage with investors to discuss their focus on alternative asset management, longevity-based assets, and personalized financial planning.

Abacus Global Management to Participate in the 26th Annual B. Riley Investor Conference
ABX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Abacus Global Management specializes in alternative asset management and data-driven wealth solutions.
  • The company emphasizes longevity-based assets and personalized financial planning leveraging proprietary analytics.
  • Senior management will hold investor meetings at the 26th Annual B. Riley Investor Conference to provide insights and updates.

ORLANDO, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NYSE: ABX), a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services with a focus on longevity-based assets and personalized financial planning, today announced that it will participate in the 26th Annual B. Riley Investor Conference, taking place May 20-21, 2026 at The Ritz Carlton in Marina del Rey, CA.

Members of Abacus management, including Chief Financial Officer and Chief Operating Officer Bill McCauley, Chief Investment Officer Elena Plesco and Managing Director of Investor Relations David Jackson, will be available for one-on-one and small-group investor meetings throughout the day on Thursday, May 21st.

To request a meeting with Abacus management, please email the Company's Investor Relations team at ir@abacusgm.com.

About Abacus

Abacus Global Management (NYSE: ABX) is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide.

For more information, please visit www.abacusgm.com

Contacts:

Investor Relations

Robert F. Phillips – SVP Investor Relations and Corporate Affairs
rob@abacusgm.com
(321) 290-1198

David Jackson – Managing Director of Investor Relations
david@abacusgm.com
(321) 299-0716

Abacus Global Management Public Relations
press@abacusgm.com


Risks

  • Market reception to information shared at the investor conference is uncertain and may not lead to immediate positive stock movements.
  • Sector-specific risks include fluctuations in alternative asset markets and evolving investor preferences in financial planning.
  • Technological innovation pace may impact competitive positioning within financial services and wealth management sectors.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026